Issues 4 observations
Cipla announced that the United States Food and Drug Administration (USFDA) conducted a routine cGMP inspection for both Formulations and APIs at the company's manufacturing facility in Patalganga from 4 November 2019 to 13 November 2019.The inspection ended with 4 observations, none of which were repeat or related to data integrity. The Company is committed to addressing these observations and will submit its response to the agency within the stipulated time
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
